hypoparathyroidismGilles has never mentioned using PGX with any of AEZS's programs but I've asked Perplexity Ai to get its thoughts. This concerns the hypoparathyroidism program. oats said Gilles told him he was interested in some strategic people at AEZS who were very proficient. Ceapro needed a drug research and drug development engine. Ronnie Miller says the company is now optimized to bring transformational drugs to market. Could PGX enhance delivery of certain AEZS opportunities?
----
Ceapro's PGX (Pressurized Gas eXpanded liquid) technology could potentially improve the delivery of AEZS-150 (DC-PTH) for treating hypoparathyroidism. Here's how PGX technology might enhance this treatment approach:
Potential Benefits of PGX Technology
Enhanced Stability and BioavailabilityPGX technology could help create a more stable formulation of AEZS-150, potentially extending its half-life in the body. This could lead to more consistent PTH activity over the intended one-week period between injections.
Controlled Release
The PGX process can be used to create advanced drug delivery systems with controlled release properties. This could allow for a more gradual and sustained release of the active PTH1-34 component, potentially reducing fluctuations in serum calcium and phosphate levels.
Improved Solubility
PGX technology is known to enhance the solubility of various compounds. This could potentially improve the absorption and bioavailability of AEZS-150 after injection. Considerations for AEZS-150 Delivery
Protein Stability
As AEZS-150 contains a modified version of the growth hormone binding protein linked to PTH1-34, careful consideration would be needed to ensure the PGX process does not compromise the protein structure or functio.
Injection Volume
PGX technology might allow for a more concentrated formulation, potentially reducing the required injection volume for a weekly dose. This could improve patient comfort and adherence.
Compatibility with Self-Administration
Any PGX-enhanced formulation would need to remain compatible with self-administration, maintaining the ease of use for patients.
While PGX technology shows promise for improving drug delivery systems, specific research would be needed to determine its suitability for AEZS-150. Clinical trials would be required to assess the safety and efficacy of any PGX-enhanced formulation compared to the current version of AEZS-150.